• Aptevo Therapeutics filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone aimed at solid tumors.
• Platform design supports multiple development paths from one targeting architecture, including radiopharmaceutical candidates or T-cell engager constructs.
• Strategy targets tumor localization via Nectin-4 while engaging PD-L1 to counter immune suppression, seeking better selectivity than single-target approaches.
• Backbone extends the company’s ADAPTIR and ADAPTIR-FLEX platforms, positioning the pipeline for additional payloads or immune-modulating functions.
• Filing strengthens intellectual property coverage, supporting partnering discussions and a broader solid-tumor pipeline build-out.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.